OBJECTIVE: The first goal of this investigation was to determine the rate of appropriate initial antimicrobial administration to patients with methicillin-resistant Staphylococcus aureus (MRSA) sterile-site infections. Our second goal was to evaluate the influence of appropriate initial treatment of MRSA sterile-site infection on outcome. DESIGN: A retrospective, single-center, observational cohort study. SETTING: Barnes-Jewish Hospital, a 1200-bed urban teaching facility. PATIENTS: Adult patients requiring hospitalization identified to have an MRSA sterile-site infection. INTERVENTIONS: Retrospective data collection from automated hospital and pharmacy databases. MEASUREMENTS AND MAIN RESULTS: Five hundred forty-nine patients with S. aureus sterile site infections were identified during a 3-yr period (January 2002 through December 2004). One hundred twenty-seven (23.1%) died during hospitalization. Hospital mortality was statistically greater for patients receiving inappropriate initial antimicrobial treatment (n = 380) within 24 hrs of a positive culture than for those receiving appropriate initial treatment (n = 169) (26.1% vs. 16.6%; p = .015). Multiple logistic regression analysis identified inappropriate initial antimicrobial treatment (adjusted odds ratio [AOR], 1.92; 95% confidence interval [CI], 1.48-2.50; p = .0134), vasopressor administration (AOR, 5.49; 95% CI, 4.08-7.38; p < .001), and increasing age (1-yr increments) (AOR, 1.03; 95% CI, 1.02-1.04; p < .001) as independent determinants of hospital mortality. CONCLUSIONS: Inappropriate initial antimicrobial treatment of MRSA sterile-site infections is common and is associated with an increased risk of hospital mortality. Appropriate antimicrobial treatment of MRSA sterile-site infections may be maximized by increased use of initial empirical antimicrobial treatment regimens targeting MRSA in patients at risk for this infection until organism identification and susceptibility become known.
OBJECTIVE: The first goal of this investigation was to determine the rate of appropriate initial antimicrobial administration to patients with methicillin-resistant Staphylococcus aureus (MRSA) sterile-site infections. Our second goal was to evaluate the influence of appropriate initial treatment of MRSA sterile-site infection on outcome. DESIGN: A retrospective, single-center, observational cohort study. SETTING: Barnes-Jewish Hospital, a 1200-bed urban teaching facility. PATIENTS: Adult patients requiring hospitalization identified to have an MRSA sterile-site infection. INTERVENTIONS: Retrospective data collection from automated hospital and pharmacy databases. MEASUREMENTS AND MAIN RESULTS: Five hundred forty-nine patients with S. aureus sterile site infections were identified during a 3-yr period (January 2002 through December 2004). One hundred twenty-seven (23.1%) died during hospitalization. Hospital mortality was statistically greater for patients receiving inappropriate initial antimicrobial treatment (n = 380) within 24 hrs of a positive culture than for those receiving appropriate initial treatment (n = 169) (26.1% vs. 16.6%; p = .015). Multiple logistic regression analysis identified inappropriate initial antimicrobial treatment (adjusted odds ratio [AOR], 1.92; 95% confidence interval [CI], 1.48-2.50; p = .0134), vasopressor administration (AOR, 5.49; 95% CI, 4.08-7.38; p < .001), and increasing age (1-yr increments) (AOR, 1.03; 95% CI, 1.02-1.04; p < .001) as independent determinants of hospital mortality. CONCLUSIONS: Inappropriate initial antimicrobial treatment of MRSA sterile-site infections is common and is associated with an increased risk of hospital mortality. Appropriate antimicrobial treatment of MRSA sterile-site infections may be maximized by increased use of initial empirical antimicrobial treatment regimens targeting MRSA in patients at risk for this infection until organism identification and susceptibility become known.
Authors: J Rello; D Molano; M Villabon; R Reina; R Rita-Quispe; I Previgliano; E Afonso; M I Restrepo Journal: Med Intensiva Date: 2012-06-28 Impact factor: 2.491
Authors: Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; George Sakoulas; Eli N Perencevich Journal: PLoS One Date: 2010-07-02 Impact factor: 3.240
Authors: J Kim; E-J Joo; Y E Ha; S Y Park; C-I Kang; D R Chung; J-H Song; K R Peck Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-30 Impact factor: 3.267
Authors: Scott T Micek; Katherine E Kollef; Richard M Reichley; Nareg Roubinian; Marin H Kollef Journal: Antimicrob Agents Chemother Date: 2007-08-06 Impact factor: 5.191